Evidence hub

Crohn's & IBD: cell-therapy evidence by therapy class

Across every stem-cell intervention, ClinicalTrials.gov holds 89 registered records for Crohn's & IBD — 14 recruiting, 13 at Phase 3 or 4, in 26 countries. Snapshot 2026-08-29.

Medical review statusMedically reviewedReviewed by: Stem Plus medical teamReviewed on: 2026-08-29Last evidence update: 2026-08-29Methodology and editorial standards
Clinical review team: Dr Kamelia Milcheva, Hematologist · Dr Vadym Uvarov, Board-Certified Physician · Hepatobiliary Surgeon · Candidate of Medical SciencesEditorial responsibility: StemCellAtlas research teamEducational information only. This page does not provide medical advice, diagnosis or a treatment recommendation.

The condition, and why cells are proposed

Crohn's disease is transmural intestinal inflammation with a relapsing course. Two very different cell propositions exist: local injection for perianal fistulas, which has the strongest regulatory footing in the whole field, and systemic infusion for luminal disease, which does not. Conflating them is how weak offers borrow credibility from strong evidence.

Therapy classes side by side

Therapy classRegisteredRecruitingPhase 3/4Countries
MSC526417
HSCT185110
exosomes2001
PRP2002

Counts come from separate registry queries per class; a study testing two interventions can appear in more than one row, so rows do not sum to the all-interventions total.

Geography of the research

United States accounts for about 36% of country mentions among sampled studies; 26 countries host at least one site.

CountryStudies with a site there
United States35
Spain13
France10
South Korea7
Italy7
Belgium7
China6
Israel5

The largest registered studies

Sorted by planned enrolment — size is not quality, but a 300-participant trial can answer questions a 12-participant series cannot.

StudyPhaseStatusPlanned nLead sponsorStart
NCT03279081 — Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal FistulPhase 3Completed568Tigenix S.A.U.2017-09-15
NCT00482092 — Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's DiseasePhase 3Completed330Mesoblast, Inc.2007-09-17
NCT01541579 — Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's DiseasePhase 3Completed278Tigenix S.A.U.2012-07
NCT06925594 — Phase 3 Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients With Crohn's DiseasePhase 3Recruiting228Jiangsu Topcel-KH Pharmaceutical Co., Ltd.2025-03-20
NCT00475410 — Efficacy and Safety of Adipose Stem Cells to Treat Complex Perianal Fistulas Not Associated to Crohn´s DiseasePhase 3Completed214Tigenix S.A.U.2007-02
NCT04075825 — Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal FistulaPhase 3Completed150Takeda2019-11-05

Most recently registered

StudyPhaseStatusPlanned nLead sponsorStart
NCT07740499 — TOLerogenic Potential of Hematopoietic Stem and Progenitor Cells and Inflammatory Bowel Diseasen/aNot Yet Recruitingn/aIRCCS San Raffaele2026-10
NCT07077746 — HB-adMSCs for the Treatment of Crohn's Diseasen/aRecruitingn/aHope Biosciences Research Foundation2026-07-14
NCT07010926 — A Double-Blind, Randomized, Placebo-Controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of L2-01 in Subjects With Crohn's Diseasen/aNot Yet Recruitingn/aL2 Bio, LLC2025-08-15
NCT06986382 — Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients n/aNot Yet Recruitingn/aStanford University2025-07
NCT06918808 — DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Diseasen/aRecruitingn/aDirect Biologics, LLC2025-05-19

Reading this honestly

None of these numbers say the therapy works. They say how much organised research exists and how far along it is; effect sizes live in published results, not registry entries. For Crohn's & IBD specifically, the practical question is which registered study — if any — matches the product a provider is offering, and what its outcome measures actually are.

Frequently asked

How many stem-cell trials exist for Crohn's & IBD?

89 registered records mention a stem-cell intervention for this condition (2026-08-29 snapshot), of which 14 were recruiting.

Which therapy class is furthest along for Crohn's & IBD?

Ranked by Phase 3/4 records: MSC (4), HSCT (1), exosomes (0), PRP (0).

Does a recruiting trial mean I can be treated?

No. Trials have eligibility criteria, and joining one is not the same as buying a treatment. Paying a clinic for an unproven intervention outside a registered study gives you neither the protections nor the data collection of a trial.

Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.

Explore all sections · Data & downloads

Download the query data

Download CSV · Download JSON

Query totals are full API matches; status, phase and country counts describe the first up to 400 returned records per query. Query classes overlap and must not be summed as unique trials. Counts are not treatment outcomes. Snapshot: 2026-08-29. Methods and field definitions.